Nick R. Leslie is a biochemist and cancer biologist. He
completed his first degree in Genetics at Cambridge University and his PhD at
Glasgow University with David Sherratt, FRS. After post-doctoral research at
the Beatson Institute for Cancer Research, he moved to Dundee to work with
Peter Downes and Philip Cohen at the inception of their pharmaceutical
collaboration, the Division of Signal Transduction Therapy. It was in Dundee
that he began studying the PI 3-kinase signaling pathway and PTEN. He was appointed
as an Independent Investigator there in 2002 and moved his lab to Heriot-Watt
University in 2013. After moving to Heriot-Watt University, he
continued this research and also initiated extensive collaborations with
bioengineers to apply novel technologies to cancer research. He was promoted to
a professor in 2017 and became the Director of Research for the School of Engineering
and Physical Sciences in 2019. Throughout this time at the Beatson Institute for Cancer Research, at the University of Dundee
Nick R. Leslie is a biochemist and cancer biologist. He
completed his first degree in Genetics at Cambridge University and his PhD at
Glasgow University with David Sherratt, FRS. After post-doctoral research at
the Beatson Institute for Cancer Research, he moved to Dundee to work with
Peter Downes and Philip Cohen at the inception of their pharmaceutical
collaboration, the Division of Signal Transduction Therapy. It was in Dundee
that he began studying the PI 3-kinase signaling pathway and PTEN. He was appointed
as an Independent Investigator there in 2002 and moved his lab to Heriot-Watt
University in 2013. After moving to Heriot-Watt University, he
continued this research and also initiated extensive collaborations with
bioengineers to apply novel technologies to cancer research. He was promoted to
a professor in 2017 and became the Director of Research for the School of Engineering
and Physical Sciences in 2019. Throughout this time at the Beatson Institute for Cancer Research, at the University of Dundee